Elutia (ELUT) Registration Filing summary

Company overview and business model

• Mission centers on humanizing medicine by leveraging biologics and local drug delivery to improve outcomes for patients with implanted medical devices, focusing on reducing complications such as infection and implant rejection.

• Core markets are Device Protection (notably EluPro and CanGaroo bioenvelopes) and Women's Health (SimpliDerm acellular dermal matrix), with legacy products in Cardiovascular sold via an exclusive distribution agreement.

• Maintains scalable internal manufacturing and R&D facilities, with recent expansion for future Women's Health product production.

Financial performance and metrics

• Reported a net loss of $53.9 million for the year ended December 31, 2024, with an accumulated deficit of $229.6 million as of that date.

• As of December 31, 2024, had $23.5 million in outstanding senior secured term loan debt and a $0.9 million exit fee liability, with a weighted average interest rate of 13.4%.

• Net tangible book value as of December 31, 2024, was $(1.55) per share; after the offering, as adjusted, would be $(0.13) per share, resulting in immediate dilution of $3.31 per share to new investors at an assumed offering price of $3.18.

Use of proceeds and capital allocation

• Net proceeds are expected to be used for working capital, product development, clinical research, sales expansion, capital expenditures, administrative expenses, debt interest, and resolution of claims related to product recalls.

• May allocate a portion of proceeds to acquisitions or investments in complementary technologies or businesses, though no current agreements exist.

• Management retains broad discretion over the use of proceeds.